Health & Medicine

STAT+: Pharmalittle: We're reading about a U.S. senator probing FDA, BioNTech founders leaving, and much more

29 sec read36 views0 listens

The co-founders of BioNTech are leaving to start a new mRNA-focused company, while BioNTech will focus on its cancer pipeline; this split aims to add value for shareholders. U.S. Senator Ron Johnson has launched an investigation into the FDA's recent denials of treatments for rare diseases, adding political pressure to the agency. For content creators, these developments highlight shifts in biotech leadership and increased scrutiny of regulatory decisions impacting drug approvals.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Tech & Gadgets10 hours ago25 sec read

How Toronto is using Clariti's AI to speed up building permit approvals

Toronto has launched a one-year pilot program with Clariti's CivCheck AI software to expedite the city's building permit approval process. This initiative aims to reduce delays caused by incomplete applications, which can add significant costs for de...

Ali Nemati

Biotech & Pharma13 hours ago28 sec read

CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial

A Phase 1 clinical trial at Charité—Universitätsmedizin Berlin has shown that CAR T-cell therapy significantly reduced disease activity in six patients with severe, treatment-refractory rheumatoid arthritis (RA), with three achieving sustained remiss...

Ali Nemati

Biotech & Pharma18 hours ago26 sec read

STAT+: Pharmalittle: We're reading about an AstraZeneca trial failure, a 'monstrous' conflict of interest, and more

AstraZeneca's heart disease trial for its experimental drug failed, showing no additional benefits for patients already on stabilizer drugs. This setback highlights challenges in a competitive market and underscores the difficulty of improving outcom...

Ali Nemati